Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.

Patients will be evaluated monthly for one year.

Participants will be assigned to one of two groups:

Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection throughout the remainder of the study Group B will receive injections of ranibizumab on an as needed basis throughout the study

You cannot take part in this study if:

1. You are pregnant or intending to become pregnant in the next 12 months or are nursing an infant
2. You are under the age of 18

Inclusion Criteria:

• age 18 or over
• active choroidal neovascularization secondary to ocular histoplasmosis
• Visual acuity between 20/25 and 20/400

Exclusion Criteria:

• pregnancy or intent to become pregnant within the next 12 months
• nursing an infant
• premenopausal women not using contraception
• prior treatment with subfoveal thermal laser
• allergy to sodium fluorescein simultaneous participation in another investigation or trial